BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 7, 2006
View Archived Issues
Anthocyanin derivative may have potential application in cardiovascular disease
Read More
Novel antimalarial targeting plasmapepsin II reported
Read More
Pharmacological profile of novel ACAT inhibitor reported by Kyoto
Read More
MDX-1100's potential in ulcerative colitis described
Read More
BXL-628 has relevant molecular effects in experimental autoimmune prostatitis
Read More
CPU-057 shows benefit in a rat model of pulmonary hypertension
Read More
AstraZeneca inlicenses Cubicin rights for China and other countries
Read More
New phase II trial investigates fenretinide in geographic atrophy
Read More
Alexza completes transaction to fund development of AZ-002 and AZ-004
Read More
Sangamo to acquire Edwards Lifesciences' angiogenesis program
Read More
Acadia to license complementary intellectual property for serotonin platform
Read More
AVI BioPharma awarded biodefense contract by Defense Threat Reduction Agency
Read More
Cypher Select Plus launched in Canada
Read More
Caprospinol clinical trials for Alzheimer's to begin early next year
Read More
Lion bioscience shareholders approve name change to Sygnis Pharma
Read More
ARYS-01 cream shows activity in patients with primary herpes zoster episodes
Read More
FM-VP4 is dose responsive with clinically significant reduction in LDL-cholesterol
Read More
New E.U. approval for Hycamtin with chemotherapy for cervical cancer
Read More
SMP-986 improves voiding efficiency in anesthetized dogs
Read More
Recent patents describe new treatment options for endocrine-related disorders
Read More
Novel treatment options for obesity reported in recent Novo Nordisk and Takeda patents
Read More
Highest doses of XR-NTX demonstrate opioid blockade for 28 days
Read More
Phase IIa trial investigates SC-12267 for rheumatoid arthritis
Read More
Avexa and TargetDrug sign binding sheet for CCR5 HIV drug program
Read More
Amgen responds to reports on use and safety of Epogen and Aranesp
Read More
Curaxin CBLC-102 studied in phase II for hormone-refractory prostate cancer
Read More
Phase III program under way for oral contraceptive NOMAC/E2
Read More
